Significance:
MALIGNANCIES, SOLID TUMORS, METASTATIC BREAST CANCER, METASTATIC MELANOMA
Data evaluating CAR T therapy in patients with solid tumors are limited. This pilot clinical trial demonstrates that intravenous cMET-directed CAR T-cell therapy is safe and feasible in patients with metastatic melanoma and metastatic breast cancer, supporting the continued evaluation of cellular therapy for patients with these malignancies.